On March 24, 2026, Ocugen reported positive 12‑month topline data from its Phase 2 ArMaDa trial of OCU410, a one-time AAV5-based modifier gene therapy for geographic atrophy secondary to dry ...
Returnal, Housemarque’s first foray into the roguelike shooter genre, was notoriously grueling and punishing, to the point where some folks bounced off it out of frustration. Saros, the studio’s ...
The postponement of Blue Cross Blue Shield of Michigan’s (BCBSM) proposed reimbursement policy affecting evaluation and management (E/M) services billed with modifier 25 marks a critical step in ...
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE)-- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced ...
f.write(f' {model.economics.Cwell.display_name}: {model.economics.Cwell.value:10.2f} {model.economics.Cwell.CurrentUnits.value}\n') if econ.cost_lateral_section.value ...
The performance enhancement of poly(ethylene terephthalate) (PET) and poly(butylene terephthalate) (PBT) blends using different impact modifiers was studied using ...
Astute Analytica has recently published a detailed and extensive report analyzing the Saudi Arabia Light Commercial Vehicle Modifiers Market. This study spans a decade-long forecast from 2024 to 2033, ...
For the quickest way to join, simply enter your email below and get access. We will send a confirmation and sign you up to our newsletter to keep you updated on all your gaming news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results